xRead - Globus and Chronic Cough (April 2024)

Wamkpah et al.

Page 25

Author Manuscript Author Manuscript Author Manuscript Author Manuscript # Patients enrolled; completed therapy (males/ females) Average age in years Comparator Treatment duration Primary outcome measure

Secondary outcome measure(s)

Percent reduction in

RSI, CSI from baseline

Number of patients who are clinical responders

(reduction in RSI by ≥6 points)

Placebo oral tablet with speech pathology treatment (5 sessions) (20) 14 weeks LCQ Cough severity VAS

24-hr cough frequency (coughs/hr) Capsaicin cough

challenge Urge-to

cough scale CAPE-V, DSI, LHQ, VHI

Limitation of symptoms on everyday activity Clinician assessment of participant ability to understand and Acoustic and implement strategies

electroglottographic analyses

None 3 months Subjective

response to therapy

Percent

reduction of cough

symptoms

from baseline

None 6 weeks RSI CSI

4 sessions Symptom

severity and frequency rating

4 sessions Perceptual

voice analysis

rated by SLPs

None 6 or more months

intervention (n patients)

Healthy Lifestyle

Education intervention program (HLE) HLE

30-min sessions (44)

30-min sessions

300 mg daily, then tapered off with speech pathology treatment (5 sessions) (20)

NR Tricyclic antidepressant: 63 1st line

tricyclic antidepressant:

63 Trigger reduction method: plant-based diet, standard reflux precautions, nasal E: 61 C: 64

saline irrigation 4–5 times daily, intranasal steroid/ Neuromodulator:

2nd line neuromodulator: gabapentin 300 mg daily, maximum 2400 mg daily

3rd line selective serotonin reuptake inhibitor: citalopram

4th line neuromodulator: pregabalin

5th line neuromodulator: oxcarbazepine if failed all the above: capsaicin spray

Experimental

intervention (n patients)

amitriptyline 10 mg daily (minimum)

amitriptyline 10 mg daily, maximum 80 mg daily

(<60 yo); desipramine 10 mg daily, maximum 80 mg daily (>60 yo)

antihistamine combination

pregabalin titrated up to

59.4 SPEech Pathology

Intervention Program for SPEICH-C CHronic Cough (SPEICH C) 30-min sessions (43)

30-min sessions

E: 58.9

C: 61.5

66; 66

(18/48)

32; 32

(8/24)

29; 29

(9/20)

(13/27)

(23/64)

(22/61)

number (year) Location Study design Stein et al (2013)

Retrospective case series

Retrospective case series

Retrospective case series

Parallel RCT 40; 35

Parallel RCT 97; 87

Parallel RCT 97; 83

Boston, MA, USA

Downers

Grove, IL, USA

Valhalla, NY, USA

Newcastle, NSW,

Australia

Newcastle, NSW,

Australia

Newcastle, NSW,

Australia

Bastian et al (2015)

Zalvan et al (2019)

Vertigan et al (2016)

Vertigan et al (2006)

Vertigan et al (2008)

Author or

clinical trial

Speech therapy

Laryngoscope . Author manuscript; available in PMC 2022 January 01.